In this special series, we review the evolution of Taiwan’s biotech industry, focusing on key policies, bioclusters as well as the major deals surrounding licensing, mergers, and acquisitions. In the forthcoming articles, we will also present industry overviews, company analyses, and biotech investor interviews to depict the current landscape and predict future directions.

In the past, Taiwan built its ICT industry as a service provider which international brands could outsource. It can take a similar approach with its burgeoning CDMO industry to accumulate experience and technical knowledge. When considering manufacturing powerhouses such as South Korea and India, which have already established their CDMO markets, Taiwan’s industrial-scale...